Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board

What are you looking for?

  • Anterior Segment
  • Cataract
  • Cornea and External Disease
  • Diabetic Macular Edema
  • Dry Eye
  • Early Onset Cataracts
  • Exclusives
  • General
  • Geographic Atrophy
  • Glaucoma
  • Industry News
  • Inherited Retinal Disease
  • IOLs
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Oculoplastics
  • Optometry
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Refractive Surgery/Vision Correction
  • Residents & Young Ophthalmologists
  • Retina
  • Retina Care 360
  • Retinopathy of Prematurity
  • Spotlight Series
  • The Interventional Glaucoma Project
  • The Ophthalmic Project
  • Trending Topics
Spotlight - The Future of Cryopreserved Amniotic Membrane in Oculoplastic Surgery
Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board
Home > Retina > New Retina Risk App Helps Patients Assess Risk for Diabetic Eye Disease
  • Retina

New Retina Risk App Helps Patients Assess Risk for Diabetic Eye Disease

Ophthalmology 360
New Retina Risk App Helps Patients Assess Risk for Diabetic Eye Disease

A new free app, Retina Risk App, is helping patients assess for risk for diabetic eye disease. More than 430 million people currently have diabetes and is expected to exceed 600 million by 2045. Approximately two-thirds of those affected develop diabetic retinopathy. If left untreated or undiagnosed, they are at high risk for blindness or visual impairment.

Retina Risk App is a clinically validated risk calculator that allows patients with diabetes to monitor their real-time risk for diabetic retinopathy. The app included guidelines as well as information on diabetes, diabetic retinopathy, and patient education to improve self-care. Users are also able to set goals and track progress, and share results. Specifically, the app supports self-management through regular eye examinations and seeking medical assistance.

The app uses a proprietary algorithm that was clinically validated in 20,000 Northern European patients with diabetes; findings have been published in several medical journals. The algorithm calculates patients’ annualized risk of developing diabetic retinopathy based on established risk factors, which accounts for 80% of established risk factors based on research data.

Further validation is needed in other patient populations. However, researchers expect the power of personal prediction to reach 90% after more detailed analysis.

 

Share

Related Content

  • Retina

Biosimilar aflibercept-ayyh demonstrates favorable real-world safety and efficacy

  • Retina

Switching to aflibercept 8 mg improved anatomical outcomes in previously treated nAMD

Neovascular Age-related Macular Degeneration: Emerging Therapies With an EYE On Treatment Frequency
  • Retina

Treat-and-extend aflibercept 8 mg improves outcomes in nAMD over 1 year

  • Retina

Intravitreal therapy in nAMD linked to lower depression and anxiety risk

  • Retina

Alternative aflibercept regimens maintained efficacy in wet AMD

  • Retina

Nanoscope Therapeutics is working on the potential first-ever optogenetic therapy for retinal diseases

Share

Editor's Picks

  • Neurotrophic Keratitis

Topical insulin shows real-world benefit in neurotrophic keratopathy

  • Retina

GLP-1 RAs have protective effects against AMD

  • Retina

Four-month injection intervals appear safe for long-term stable nAMD

Advisory Board

Saad Ahmad, MD

Ahmad A. Aref, MD, MBA

Roomasa Channa, MD

David Chow, MD, FRCS(C)

Sally L. Baxter, MD, MSc

Neel R. Desai, MD

Nadia Haqqie, MD

Simon Fung, MD, FRCOphth

Sumit Garg, MD

Ross Lakhanpal, MD, FACS

Sanjai Jalaj, MD

Anton Kolomeyer, MD, PhD

Shan Lin, MD

Steven R. Sarkisian, Jr., MD

See All
Optometry360 Logo

Ophthalmology 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

2026 Ophthalmology 360 is a trademark of International Healthcare Media, LLC. All rights reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophtalmology360 Icon